PBYI - Puma Biotechnology: A Speculative Investment At A Discount
Back in August, Puma Biotechnology (PBYI) reported their Q2 earnings that revealed NERLYNX net sales were up from the disappointing Q1 report. The Q1 results showed a drop of 25% in revenue from Q4, which forced the management to cut 2019 net sales guidance from $268M to $230M. Obviously, this decimated the share price from ~$30 per share in May and finally bottom out in the ~$8 range in early August. Since the Q2 earnings, the stock has started to pull off the bottom and showing some bullish signal heading into Q4. It